Program
ivosidenib
Also written as “Ivosidenib”, “Ivosidenib Oral Tablet” and “AG120”.
Its studies are mostly in Cholangiocarcinoma · Leukemia, Myeloid, Acute · Neoplasm Metastasis · Neoplasms, Unknown Primary, led by 6 companies.
Drug pageIvosidenib: every studyMany companies study it; this page follows only the 13 they lead. All 55 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticalsits history only | 50 open or running | phase 1since Jul 1, 2015 | Jul 1, 2015 | none ahead |
| Servier Bio-Innovationits history only | 32 open or running | phase 3since Nov 7, 2023 | Apr 21, 2023 | Feb 1, 2028phase 3 · NCT06127407 |
| Servier Affaires Médicales | 22 open or running | phase 3since May 17, 2023 | May 17, 2023 | Oct 15, 2027phase 3 · NCT05907057 |
| CStone Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 29, 2019 | Oct 29, 2019 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
| Servierits history only | 11 open or running | phase 2since Sep 14, 2023 | Sep 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Servier Affaires Médicales only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2015Named ivosidenibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AG120
- May 17, 2023First study: phase 3 study in CholangiocarcinomaFirst studyNCT05876754 · 299 enrolled · Armenia, Australia, Austria and more
- Jun 8, 2023Phase 3 study in Leukemia, Myeloid, AcuteNCT05907057 · 245 planned · Austria, France, Italy and more
Ahead
- Oct 15, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT05907057
- Dec 1, 2027Primary completion: phase 3 study in CholangiocarcinomaNCT05876754
TargetBeta
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 5 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| safusidenibrule | Nuvation Bio | phase 3 | 6 |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 5 |
Studies
All 2 Servier Affaires Médicales leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05907057Leukemia, Myeloid, Acute · Austria, France, Italy and more | 3 | Recruiting | Oct 15, 2027 | 245 |
| NCT05876754Cholangiocarcinoma · Armenia, Australia, Austria and more | 3 | Active, not recruiting | Dec 1, 2027 | 299 |
How it is read
Names in the registry
- “Ivosidenib”, 3 entries
- “Ivosidenib Oral Tablet”, 2 entries
- “AG120”, 2 entries
- “Ivosidenib 500mg”, 1 entry
- “Ivosidenib 500mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 3 studies
- Leukemia, Myeloid, Acute, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, Unknown Primary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.